Bayesian Capital Management’s ADMA Biologics ADMA Stock Holding History

Bayesian Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-47,700	Closed	-$430K	–	227
2026 Q1	$430K	Buy	+47,700	New	+$753K	0.52%	64
2024 Q3	–	Sell	-15,615	Closed	-$175K	–	648
2024 Q2	$175K	Buy	+15,615	New	+$131K	0.02%	619
2024 Q1	–	Sell	-57,915	Closed	-$262K	–	754
2023 Q4	$262K	Sell	57,915 -18,185	-24%	-$67.3K	0.03%	543
2023 Q3	$272K	Buy	+76,100	New	+$293K	0.03%	491
2023 Q2	–	Sell	-11,146	Closed	-$36.9K	–	755
2023 Q1	$36.9K	Sell	11,146 -30,854	-73%	-$107K	﹤0.01%	721
2022 Q4	$163K	Buy	+42,000	New	+$130K	0.02%	622
2022 Q3	–	Sell	-55,300	Closed	-$109K	–	670
2022 Q2	$109K	Buy	+55,300	New	+$109K	0.02%	680

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bayesian Capital Management's ADMA Position: Q2 2026 in Review

Bayesian Capital Management sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 47,700 shares — an estimated $430K sold.

Bayesian Capital Management first reported a position in ADMA in Q2 2022 and held it in 7 quarters. The position peaked at $430K in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Bayesian Capital Management reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
Bayesian Capital Management sold 47,700 ADMA Biologics shares in Q2 2026, an estimated $430K.
Bayesian Capital Management first reported a position in ADMA Biologics in Q2 2022 and held it in 7 quarters.
Bayesian Capital Management's ADMA Biologics position peaked at $430K in Q1 2026.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.